The Epax Omega-3 product line will complement Pelagia's existing product offerings and add to the strategy of increasing our portfolio of value added products
FMC Corporation has announced that Pelagia has signed a definitive agreement with FMC to acquire their Epax Omega-3 business. Epax is a leading global brand of concentrated marine-based omega-3 fatty acids for dietary supplement and pharmaceutical preparations. The Epax Omega-3 product line will complement Pelagia's existing product offerings and add to the strategy of increasing our portfolio of value added products. The closing of the agreement will be in August.
CEO Egil Magne Haugstad of Pelagia expresses satisfaction with the agreement: "Pelagia has a responsibility and takes long term development initiative through innovation to increase the market value of our pelagic resources. We believe this long term achievement will be beneficial to all stakeholder including the fishermen The acquisition will give us access to production resources, networks and markets for refined marine oils for direct human consumption. We hope and believe that we can create exciting synergies between the resources in Epax and the core strength of Pelagia. We expect, that parts of our fantastic North Atlantic fish oil product offerings can be further refined and gain direct Human consumption market access through future and existing processes developed by Epax."